Hepatocyte growth factor activators, inhibitors and antagonists and their implication in cancer intervention

Histology and Histopathology

Volumn 16, Issue 1, 2001, Pages 251-268

  Parr, C ^a   Jiang, W G ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

cMET protooncogene; Hepatocyte growth factor; HGF SF activator; HGF SF activator inhibitor; HGF SF antagonists

Indexed keywords

APROTININ; CALCIUM; CELL ADHESION MOLECULE; GELDANAMYCIN; INTERLEUKIN 12; INTERLEUKIN 4; MESSENGER RNA; POLYUNSATURATED FATTY ACID; RETINOIC ACID; SCATTER FACTOR; SCATTER FACTOR ACTIVATOR; SCATTER FACTOR ACTIVATOR INHIBITOR; SCATTER FACTOR ANTAGONIST; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; CANCER; CANCER CELL; CANCER GROWTH; CANCER THERAPY; CELL ADHESION; CELL CYCLE; CELL GROWTH; CELL MOTILITY; CELL PROLIFERATION; ENZYME ACTIVATION; HUMAN; KRINGLE DOMAIN; NONHUMAN; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; STRUCTURE ANALYSIS; TISSUE INTERACTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; HEPATOCYTE GROWTH FACTOR; HUMANS; LIVER NEOPLASMS; SERINE ENDOPEPTIDASES;

EID: 0035132010     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (128)

1. Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression
2. Differential killing of human carcinoma cells supplemented with n-3 and n-6 polyunsaturated fatty acids
3. Scatter factor (SF) regulation of matrix metalloproteinase production by oral carcinoma cells
4. Regulation of the urokinase-type plasminogen activator gene by the oncogene Tpr-Met involves GRB2
5. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth
6. Identification of a competitive HGF antagonist encoded by an alternative transcript
7. Purification and characterisation of a novel hyaluronan-binding protein (PHBP) from human plasma: It has three EGF, a kringle and a serine protease domain, similar to hepatocyte growth factor activator
8. Hepatocyte growth-factor (HGF)/NK1 is a naturally-occurring HGF scatter factor variant with partial agonist-antagonist activity
9. Hepatocyte growth factor is a potent angiogenic factor, which stimulates endothelial-cell motility and growth
10. Molecular-cloning of a new transforming gene from a chemically transformed human cell-line
11. Hepatocyte growth factor stimulates motility, chemotaxis and mitogenesis in ovarian carcinoma cells expressing high levels of c-met
12. HGF/NK4 is a specific antagonist for pleiotrophic actions of hepatocye growth factor
13. Protease inhibitors: Role and potential therapeutic use in human cancer
14. Characterisation of placental bikunin, a novel human serine protease inhibitor
15. Expression of the met hepatocyte growth-factor receptor in human pancreatic-cancer
16. Mechanisms of hepatocyte growth-factor stimulation of keratinocyte metalloproteinase production
17. Modulation of melanoma cell adhesion to basement membrane components by retinoic acid
18. The molecular basis of blood coagulation
19. Processing of hepatocyte growth factor to the heterodimeric form is required for biological activity
20. Scatter factor induces blood-vessel formation in vivo
21. Opposing actions of hepatocyte growth factor and basic fibroblast growth factor on cell contact, intracellular free calcium levels, and rat ovarian surface epithelial cell viability
22. Inhibition of motility, dissociation, and invasion of human lung cancer cells by invasion inhibiting factor 2
23. A functional domain in the heavy-chain of scatter factor hepatocyte growth-factor binds the c-met receptor and induces cell-dissociation but not mitogenesis
24. Immunoreactivity for hepatocyte growth factor scatter factor and its receptor, met, in human lung carcinomas and malignant mesotheliomas
25. Hepatocyte growth factor and its receptor c-met regulate both cell-growth and invasion of human pancreatic-cancer
26. Retinoic acid inhibition of human melanoma cell invasion through a reconstituted basement membrane and its relation to decreases in the expression of proteolytic enzymes and motility factor receptor
27. Inhibition of motility and invasion of human colon cancer cells by interleukin-12
28. Expression of α-, β- and γ- catenin in human colorectal cancer
29. Regulation of endothelial CD44 expression and endothelium-tumour cell interactions by hepatocyte growth factor/scatter factor
30. Interleukin-12, an emerging anti-tumour cytokine
31. HGF/SF regulates the phosphorylatin of β-catenin and cell-cell adhesion in cancer cells
32. Up-regulation of the expression of hepatocyte growth factor activator (HGFA) in breast cancer
33. NK4, a HGF/SF variant, inhibits in vitro invasiveness of breast cancer cells
34. Inhibition of invasion of epithelial cells by Tiam1-Rac signaling
35. Essential fatty acids, lipid peroxidation, and cancer
36. Hepatocyte growth factor and its receptor (c-met) in prostatic-carcinoma
37. Purification and characterisation of tumour invasion-inhibiting factors
38. A potent anti-metastatic activity of tumour invasion-inhibiting factor-2 and albumin conjugate
39. Inhibitory effects of tumor invasion-inhibiting factor-2 and its conjugate on disseminating tumor-cells
40. Hepatocyte growth factor activator inhibitor type 2 (HAI-2) lacking the first Kunitz-type serine proteinase inhibitor domain is a predominant product in mouse but not in human
41. E-cadherin and its associated protein catenins, cancer invasion and metastasis
42. Hepatocyte growth factor and c-met, a cytokine playing multiple and converse roles
43. β-catenin, cell adhesion and beyond
44. Regulation of spreading and growth of human colon cancer cells by hepatocyte growth factor
45. Hepatocyte growth factor/scatter factor, liver regeneration and cancer metastases
46. Inhibition of HGF/SF induced membrane ruffling and cell motility by transient elevation of cytosolic free calcium
47. Inhibition of invasion and motility of human colon cancer cells by gamma linolenic acid
48. Regulation of the expression of E-cadherin on human cancer cells by gamma linolenic acid
49. Inhibition of motility and invasion by invasion inhibiting factor 2 on human colon cancer cells
50. Hepatocyte growth factor/scatter factor induces tyrosine phosphorylation of focal adhesion kinase (FAK) and paxillin and enhances cell-matrix interactions
51. Inhibition of membrane ruffling and ezrin translocation by gamma linolenic acid
52. Gamma linolenic acid (GLA) inhibits tyrosine phosphorylation of focal adhesion kinase (FAK) and paxillin and tumour cell-matrix interaction
53. Gamma linolenic acid regulates gap junction communication in endothelial cells and their interaction with tumour cells
54. Essential fatty acids, the molecular and cellular mechanisms of their anticancer action and clinical implications
55. Hepatocyte growth factor/scatter factor/scatter factor, the molecular, cellular and clinical implications in cancer
56. Antagonistic effects of NK4, a novel HGF variant, on the in vitro angiogenesis of human vascular endothelial cells
57. Peroxisome proliferator activated receptor gamma (PPAR-gamma) mediates the action of gamma linolenic acid in breast cancer cells
58. Participation of c-met in the progression of human gastric cancers: Anti-c-met oligonucleotides inhibit proliferation or invasiveness of gastric cancer cells
59. Evaluation of hepatocyte growth factor activator inhibitor expression in normal and malignant colonic mucosa
60. Distribution of hepatocyte growth factor activator inhibitor type 1 (HAI-1) in human tissues: Cellular surface localisation of HAI-1 in simple columnar epithelium and its modulated expression in injured and regenerative tissues
61. Purification and cloning of hepatocyte growth factor activator inhibitor type 2, a Kunitz-type serine protease inhibitor
62. Involvement of hepatocyte growth factor in increased integrin expression on HepG2 cells triggered by adhesion to endothelial cells
63. Production and activation of hepatocyte growth factor during the healing of rat gastric ulcers
64. Hepatocyte growth-factor elevates the activity levels of glycolipid sulfotransferases in renal-cell carcinoma-cells
65. Hepatocyte growth-factor and retinoc acid exert opposite effects on synthesis of type-1 and type-2 acute-phase proteins in rat hepatoma-cells
66. Protein inhibitors of proteinases
67. Potent and selective inhibitors of the met (HGF/SF receptor) tyrosine kinase block HGF/SF induced tumour cell growth and invasion
68. Effect of hepatocyte growth factor on cell cycle and c-met expression in human gastric cancer cells
69. Generation and characterization of a competitive antagonist of human hepatocyte growth factor, HGF/NK1
70. Suppression of melanoma cell motility factor receptor expression by retinoic acid
71. Intratumoral delivery of hepatocyte growth factor antagonist (HGF/NK4) by adenoviral vector suppresses the tumour growth of human long cancers in vivo
72. Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA
73. Hepatocyte growth factor activator: A possible regulator of morphogenesis during fetal development of the rat gastrointestinal tract
74. Hepatocyte growth-factor scatter factor induces tyrosine phosphorylation of focal adhesion kinase (p125FAK)) and promotes migration and invasion by oral squamous-cell carcinoma-cells
75. Cooperative interaction between α- and β-chains of hepatocyte growth factor on c-met receptor confers ligand-induced receptor tyrosine phosphorylation and multiple biological responses
76. Molecular-cloning and sequence-analysis of the cDNA for a human serine protease responsible for activation of hepatocyte growth-factor - Structural similarity of the protease precursor to blood-coagulation factor-XII
77. Proteolytic activation of hepatocyte growth factor in response to tissue injury
78. Activation of hepatocyte growth factor, in the injured tissues, is mediated by hepatocyte growth factor activator
79. Structural organisation and chromosomal localization of the human hepatocyte growth factor activator gene. Phylogenetic and functional relationship with blood coagulation factor XII, urokinase, and tissue-type plasminogen activator
80. Proteolytic activation of a large single-chain precursor of hepatocyte growth factor by extracellular serine-protease
81. Purification and characterisation of hepatocyte growth factor (HGF)-converting enzyme: Activation of pro-HGF
82. HGF/SF inhibits junctional communication
83. Cooperative roles of hepatocyte growth-factor and plasminogen-activator in tubular morphogenesis by human microvascular endothelial-cells
84. Concomitant expression of hepatocyte growth factor (HGF), HGF activator and c-met genes in human glioma cells in vitro
85. Cloning of a new Kunitz-type protease inhibitor with a putative transmembrane domain overexpressed in pancreatic cancer
86. Molecular-cloning and expression of human hepatocyte growth factor
87. Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-Met
88. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth-factor scatter factor
89. Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction
90. Induction of hepatocyte growth factor activator messenger RNA in the liver following tissue injury and acute inflammation
91. Dissociation of met-mediated biological responses in vivo: The natural hepatocyte growth factor/scatter factor splice variant NK2 antagonises growth but facilitates metastasis
92. Growth and differentiation factors inhibit the migratory phenotype of cultured neonatal rat hepatocytes induced by HGF/SF
93. NK4, a new HGF/SF variant, is an antagonist to the influence of HGF/SF on the motility and invasion of colon cancer cells
94. Inhibition of junction assembly in cultured epithelial cells by hepatocyte growth factor scatter factor is concomitant with increased stability and altered phosphorylation of the soluble junctional molecules
95. Functional characterization of Kunitz domains in hepatocyte growth factor activator inhibitor type 2
96. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumour antibiotics radicicol and geldanamycin
97. Regulation of endothelial-cell migration and capillary-like tube formation by scatter factor
98. Heparin induces dimerization and confers proliferative activity onto the hepatocyte growth-factor antagonists NK1 and NK2
99. Tyrosine phosphorylation of beta-catenin and plakoglobin enhanced by hepatocyte growth factor and epidermal growth-factor in human carcinoma-cells
100. A novel protease obtained from FBS-containing culture supernatant, that processes single chain form hepatocyte growth factor to 2 chain form in serum-free culture
101. Activation of the zymogen of hepatocyte growth factor by thrombin
102. Activation of hepatocyte growth factor by 2 homologous proteases, blood coagulation factor XIIA and hepatocyte growth factor activator
103. Hepatocyte growth factor activator inhibitor, a novel Kunitz-type serine protease inhibitor
104. Multiple sites of proteolytic cleavage to release soluble forms of hepatocyte growth factor activator inhibitor type 1 from a transmembrane form
105. Stimulatory effects of hepatocyte growth factor on normal and neoplastic human bronchial epithelial-cells
106. The protease inhibitor properties of the Alzheimer's β-Amyoid precursor protein
107. Multiparametric prognostic evaluation of biological factors in primary breast cancer
108. Hepatocyte growth factor stimulates proliferation, migration, and lumen formation of human endometrial epithelial cells in vitro
109. Isolation and characterization of the plasma hyaluronan-binding protein (PHBP) gene (HABP2)
110. Hepatocyte growth factor has potent anti-proliferative activity in various tumor cell lines
111. Disruption of the function of tumor-suppressor gene p53 by the hepatitis-β virus x-protein and hepatocarcinogenesis
112. Hepatocyte growth-factor (HGF)-induced cell-migration is negatively modulated by epidermal growth-factor through tyrosine phosphorylation of the HGF receptor
113. Effect of hepatocyte growth-factor on the expression of E-cadherin and P-cadherin in gastric-carcinoma cell-lines
114. Structural and functional characterisation of factor XII
115. Interleukin-4 inhibits hepatocyte growth factor-induced invasion and migration of colon carcinomas
116. Inhibition of transforming activity of tyrosine kinase oncogenes by herbimycin A
117. Placental defect and embyonic lethality in mice lacking hepatocyte growth factor/scatter factor
118. Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor - The case for paracrine amplification of angiogenesis
119. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-Met-urokinase plasminogen activator-plasmin proteolytic network
120. Hepatocyte growth-factor and its receptor are involved in migration of lymphoma-cells
121. Hepatocyte growth factor scatter factor promotes adhesion of lymphoma cells to extracellular matrix molecules via alpha(4)beta(1) and alpha(5)beta(1) integrins
122. Inhibition of heat shock protein HSP90-pp60-src heteroprotein complex formation by benzoquinone ansamycin: Essential role for stress proteins in oncogenic transformation
123. Hepatocyte growth-factor stimulates expression of plasminogen-activator inhibitor type-1 and tissue factor in HEPG2 cells
124. Reciprocal regulation of prothrombin secretion and tyrosine aminotransferase induction in hepatocytes
125. Astroglial expression of hepatocyte growth factor and hepatocyte growth factor activator in human brain tissues
126. White matter astrocytes produce hepatocyte growth factor activator inhibitor in human brain tissues
127. Indentification of the N-terminal residue of the heavy chain of both native and recombinant human hepatocyte growth factor